Farr Institute of Health Informatics Research, London, UK.
UCL Institute of Health Informatics, University College London, London, UK.
Eur J Heart Fail. 2017 Sep;19(9):1119-1127. doi: 10.1002/ejhf.709. Epub 2016 Dec 23.
The prognosis of patients hospitalized for worsening heart failure (HF) is well described, but not that of patients managed solely in non-acute settings such as primary care or secondary outpatient care. We assessed the distribution of HF across levels of healthcare, and assessed the prognostic differences for patients with HF either recorded in primary care (including secondary outpatient care) (PC), hospital admissions alone, or known in both contexts.
This study was part of the CALIBER programme, which comprises linked data from primary care, hospital admissions, and death certificates for 2.1 million inhabitants of England. We identified 89 554 patients with newly recorded HF, of whom 23 547 (26%) were recorded in PC but never hospitalized, 30 629 (34%) in hospital admissions but not known in PC, 23 681 (27%) in both, and 11 697 (13%) in death certificates only. The highest prescription rates of ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists was found in patients known in both contexts. The respective 5-year survival in the first three groups was 43.9% [95% confidence interval (CI) 43.2-44.6%], 21.7% (95% CI 21.1-22.2%), and 39.8% (95% CI 39.2-40.5%), compared with 88.1% (95% CI 87.9-88.3%) in the age- and sex-matched general population.
In the general population, one in four patients with HF will not be hospitalized for worsening HF within a median follow-up of 1.7 years, yet they still have a poor 5-year prognosis. Patients admitted to hospital with worsening HF but not known with HF in primary care have the worst prognosis and management. Mitigating the prognostic burden of HF requires greater consistency across primary and secondary care in the identification, profiling, and treatment of patients.
NCT02551016.
住院治疗的心力衰竭(HF)恶化患者的预后已有明确描述,但在初级保健或二级门诊等非急性治疗环境中仅接受管理的患者的预后则不然。我们评估了 HF 在各级医疗保健中的分布情况,并评估了在初级保健(包括二级门诊)(PC)中记录的 HF 患者、仅住院治疗的 HF 患者或在这两种情况下都已知的 HF 患者的预后差异。
这项研究是 CALIBER 计划的一部分,该计划包含英格兰 210 万居民的初级保健、住院和死亡证明的相关数据。我们确定了 89554 例新记录的 HF 患者,其中 23547 例(26%)在 PC 中记录但从未住院治疗,30629 例(34%)仅住院治疗但在 PC 中未知,23681 例(27%)在 PC 和住院治疗中都有记录,11697 例(13%)仅在死亡证明中记录。在 PC 和住院治疗中都已知的患者中,ACE 抑制剂、β受体阻滞剂和盐皮质激素受体拮抗剂的处方率最高。在前三组中,5 年生存率分别为 43.9%[95%置信区间(CI)为 43.2-44.6%]、21.7%(95%CI 为 21.1-22.2%)和 39.8%(95%CI 为 39.2-40.5%),而年龄和性别匹配的一般人群中这一比例为 88.1%(95%CI 为 87.9-88.3%)。
在一般人群中,每 4 例 HF 患者中就有 1 例在中位数为 1.7 年的随访期间不会因 HF 恶化而住院,但他们仍有较差的 5 年预后。因 HF 恶化而住院但在初级保健中未被诊断为 HF 的患者预后最差,管理最差。要减轻 HF 的预后负担,就需要在初级保健和二级保健中,在识别、评估和治疗患者方面更加一致。
NCT02551016。